



  NK cells and some T cells express members of a 
multigenic family of killer cell Ig-like receptors (KIRs)3 
that recognize polymorphic class I MHC molecules 
on target cells (reviewed in refs. 1-4). Both natural 
cytotoxicity and antibody dependent cell cytotoxicity 
of NK cells, and CD3/TCR dependent cytotoxicity 
of T cells are inhibited by the coengagement of KIRs 
and activating receptors such as FcR and TCR (5-8). 
Recent studies have suggested that KIR plays a role 
in the survival of memory-phenotype T cells (9,10) 
and in the inhibition of T cell activation induced cell 
death (AICD) (9,11,12). However, the exact mecha-
nism of the AICD inhibition mediated by KIR has 
not been revealed yet. Inhibitory KIRs (KIR here-
after) are type I transmembrane glycoproteins belong-
ing to the Ig superfamily and consist of either two 
(for p58 KIR and KIR103: KIR2D family) or three 
(for p70 KIR: KIR3D family) extracellular Ig-related 
domains, a transmembrane part and a cytoplasmic tail 
(13-16). The extracellular domain of KIR specifically 
recognizes particular class I MHC molecules express-
ed on target cells (17-20). The cytoplasmic tail of 
KIR contains either one (for KIR103) or two (for 
p58 and p70 KIR) immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) that function in triggering 
an inhibitory signal transduction that, in turn, pre-
vents killer cell-mediated cytotoxicity (21-24). The 
ITIM, which has the consensus sequence of (I/V) 
xYxx (L/V), was originally found in the cytoplasmic 
tail of FcγRIIB (25,26). FcγRIIB has also been 
shown to transmit the inhibitory signals in B cell ac-
tivation by recruitment of SH2-containing inositol 
phosphatase (SHIP) upon tyrosine phosphorylation 
of the ITIM (25,27,28). The consensus sequence of 
ITIM is similar but clearly distinguishable from the 
immunoreceptor tyrosine-based activation motif (ITAM) 
found in the signaling molecules associated with se-
veral lymphocyte antigen receptors (29,30).
  Upon engagement of KIR, tyrosine residues in 
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ITIMs are phosphorylated by a src-family protein ty-
rosine kinase (like p56 Lck), and in turn a SH2-con-
taining protein tyrosine phosphatase (SHP), SHP-1, is 
recruited to the phosphotyrosyl residues (21-24,31). It 
has also been shown that another SHP, SHP-2 (31, 
32), and the p85α regulatory subunit of phosphatidy-
linositol (PI) 3-kinase (32) are recruited to the pho-
sphotyrosyl residues of KIR. The functional impor-
tance of SHP-1 in the KIR-mediated inhibition of 
NK cell activation is further supported by the obser-
vation that the overexpression of a dominant negative 
form of SHP-1 reverses the inhibitory effect of KIR 
(21,22). It is thought that the inhibitory effect of KIR 
results from the dephosphorylation of phospho-tyro-
sine residues in signaling molecules involved in the 
activating signal transduction pathway by SHP (SHP- 
1 or SHP-2) recruited to the KIR. For FcR-mediated 
ADCC of NK cells, Binstadt et al. (21) reported that 
coengagement of FcR and KIR inhibited the pho-
sphorylation of FcR-associated signaling molecules in-
cluding TCRζ, ZAP-70 and PLC-γ. Similarly, when 
ζ, ZAP-70, and Lck were coexpressed with SHP-1 
in Sf21 insect cells, the levels of tyrosine phosphory-
lation in these molecules decreased substantially (33). 
It has also been demonstrated that class I MHC re-
cognition by KIR blocks the formation of a complex 
between tyrosine-phosphorylated pp36 (LAT) and 
PLC-γ in human NK cells (34). And Binstadt et al. 
have demonstrated that the SH2-containing leukocyte 
protein 76 (SLP-76) may be a specific target for de-
phosphorylation by SHP-1 in T cells and NK cells 
(35). These results suggest that SHP recruited to KIR 
may dephosphorylate those signaling molecules in 
NK cells and T cells. 
  Shc is an adaptor protein composed of a unique 
N-terminal phospho-tyrosine binding domain (PTB), 
a glycine/proline-rich collagen homology domain (CH) 
and a C-terminal SH2 domain (36-38). Shc is ubiqui-
tously expressed in three isoforms of 46, 52, and 66 
kDa, but only the 46 and 52 kDa forms are present 
in hematopoietic cells (36). Shc has been implicated 
in Ras activation triggered by a number of receptors, 
including growth factor receptors, antigen receptors 
and cytokine receptors (reviewed in refs. 39,40). The 
SH2 and PTB domains of Shc have been shown to 
interact with the tyrosine phosphorylated receptors. 
Shc is tyrosine phosphorylated upon stimulation of 
the receptors and subsequently it interacts with Grb2 
through the CH domain. The Shc：Grb2 complex, 
in turn, associates with the GTP/GDP exchange fac-
tor, SOS, and finally leads to Ras activation. Shc can 
also activate the Akt pathway via Shc-Grb2-Gab2- 
PI3K (phosphatidylinositol 3-kinase) in B cells (41).
  In this report, by in vitro coprecipitation experi-
ments and transfection analyses, we showed that KIR 
associates with an adaptor protein Shc in resting cells. 
We further demonstrated that Shc is replaced by SHP 
upon engagement of KIR by antibody.
Materials and Methods 
Cell lines. The human T cell lymphoma cell line, Jurkat 
was obtained from the American Type Culture Col-
lection (ATCC, Rockville, MD) and maintained in 
culture with RPMI 1640 medium (Flow Laboratories, 
Rockville, MD) supplemented with 10% (V/V) Fetal 
Bovine Serum (FBS, Sigma, St. Louis, MO), 1% L- 
glutamine and 1% antibiotic solution. Human embryonic 
kidney epithelial cells expressing SV 40 large T antigen 
(293T) were obtained from the ATCC and cultured in 
Dulbecco's modified Eagle medium (DMEM)(Flow 
Laboratories, Rockville, MD) supplemented with 10% 
FBS 1% L-glutamine and 1% antibiotic solution.
Antibodies and other reagents. Anti-phospho tyrosine an-
tibody (PY20), anti-SHP-1, anti-SHP-2, anti-Grb2 
and anti-Shc antibodies were purchased from Trans-
duction Laboratories (Lexington, KY). Fluorescein 
isothiocyanate (FITC) conjugated anti-mouse IgG 
and Texas-red conjugated anti-rabbit IgG were ob-
tained from Vector Laboratories (Burlingamme, CA), 
and PE-conjugated anti-mouse IgG and anti-CD8 
antibodies were from Beckton Dickinson (San Jose, 
CA). Dithiobissuccinimidyl propionate (DSP) was 
purchased from Pierce (Rockford, IL). Ni-NTA resin 
was obtained from Qiagen (Santa Clarita, CA), and 
protein A-agarose and protein G-agarose were from 
Boeringer Manheim (Indianapolis, IN). cDNA of a 
p70 KIR (NKB1) was a kind gift from Dr. Lanier 
(DNAX Research Inst., Palo Alto, CA). Polyclonal 
antibodies to the cytoplasmic tail of KIR were pro-
duced in mice using the bacterially expressed His-tag 
fusion protein of KIR (His-CytKIR; refs. 42,43). Brie-
fly, the His-CytKIR protein was further purified on 
SDS polyacrylamide gels and the protein band was 
excised with a scalpel. The gel slices were homo-
genized and injected into mice intraperitoneally. A 
booster injection was given 2 weeks after the primary 
immunization. Another two booster injections were 
given every two weeks, and the animals were bled 2 
weeks later.
His-tag and CD8 fusion constructs of KIR cytoplasmic tail, 
and other DNA constructs. The His-tag fusion protein 
construct of a p70 KIR (NKB1; ref. 14) cytoplasmic 
tail (pHis-CytKIR) was described previously (42,43), 
and the generation of plasmid containing the extra-
cellular and transmembrane portion of CD8α, pCD 
8T, was also described previously (44). A CD8 fusion 
construct of KIR cytoplasmic tail was generated by 
subcloning the cytoplasmic tail of NKB1 into the 
pCD8T. Briefly, the cytoplasmic tail of NKB1 was 
amplified by PCR with primers 5'-GGGGAATTCC 
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ATCTCTGGTGCTCCAACAAAAAAAAT-3' and 5'- 
GGGGGATCCTCATGGGCAGGAGACAACTTT
GG-3'. The amplified DNAs were cloned into EcoRI 
and BamHI sites of pBluscript (Strategene, La Jolla, 
CA) and verified by nucleotide sequencing. Then the 
KIR cytoplasmic fragment was inserted in frame into 
the EcoRI sites of pCD8T. The resulting chimeric 
receptor (CD8-KIR) was excised from the plasmid 
and ligated into SalI and BamHI sites of the eucar-
yotic expression vector, pHβAPr-1-neo (45). 
Metabolic labeling of Jurkat T cells/Preparation of cell lysates. 
Jurkat cells (5×106 cells) were washed with 10 ml of 
methionine-free RPMI 1640 and preincubated for 1 
hr in 10 ml of methionine-free RPMI 1640 sup-
plemented with 10% heat-inactivated dialyzed FBS. 
Cells were then incubated in the presence of 100μ
Ci/ml L-[35S]methionine at 37oC for 2 hr. After label-
ing, the cells were washed two times with cold PBS, 
and lysed in 0.5 ml of cold lysis buffer containing 
20 mM Na-Phosphate (pH 7.5), 0.15 M NaCl, 1% 
Triton X-100, 1 mM PMSF, 5μg/ml leupeptin, 5μg/ 
ml pepstatin, 0.02% NaN3, and 1 mM iodoace-
tamide. Cell lysates were cleared by centrifugation at 
13,000 rpm for 20 min, and the supernatant was used 
for coprecipitation and immunoblot analysis. Non-la-
beled Jurkat cell lysates were also similarly prepared.
Coprecipitation and Western blotting. The His-tag fusion 
protein of KIR cytoplasmic tail (His-CytKIR) was 
added to [35S]-labeled Jurkat cell lysates in the pre-
sence and absence of a chemical cross-linker (DSP, 
a final concentration of 2 mM), and incubated for 1 
hr at 4oC. The reaction mixtures were precipitated 
with Ni-NTA resin, as previously described (43). The 
precipitates were separated on 12% SDS polyacry-
lamide gels, and the gels were then fixed, dried, and 
autoradiographed. For Western blot analysis, His- 
CytKIR was mixed with Jurkat cell lysates in the pre-
sence of DSP, and incubated for 1 hr at room tem-
perature. The reaction mixtures were precipitated 
with Ni-NTA resin, and washed three times. Precipi-
tates were resolved by SDS-PAGE using 12% acryla-
mide gels, and proteins were transferred onto polyvi-
nylidene difluoride (PVDF) membranes (Immobilon- 
P; Millipore, Marlborough, MA). Western blot an-
alysis was performed with anti-Shc antibody, anti- 
Grb2 antibody, and anti-phosphotyrosine antibody, as 
previously described (43).
In vitro phosphorylation of His-CytKIR. Jurkat cell lysates 
and the His-CytKIR protein were mixed and incu-
bated in a kinase reaction buffer, as previously descri-
bed (43). After in vitro phosphorylation, the His-Cyt 
KIR was precipitated with Ni-NTA resin. The preci-
pitates were resolved on SDS PAGE gels, and the 
gels were blotted onto PVDF membranes and analyz-
ed with anti-Grb2, anti-Shc and anti-phosphotyrosine 
antibodies.
Immunofluorescence staining and Confocal Microscopy. Cells 
transfected with the pCD8T or pCD8-KIR cDNA 
were grown on sterile glass coverslides precoated 
with 1% gelatin overnight prior to antibody staining. 
36 hr after transfection, cells were fixed with ice-cold 
methanol and aceton for 10 min each and incubated 
with 3% H2O2 for 30 min at room temperature. The 
coverslides were washed three times with PBS and 
incubated with blocking solution (5% BSA, 3% nor-
mal horse serum, 0.3% Tritonx-100 in PBS) for 3 hr. 
The cells were simultaneously stained by incubating 
them with anti CD8 antibody ascites (1：100) follow-
ed by a goat antiserum against mouse IgG coupled 
to FITC and rabbit anti-Shc antibody followed by a 
goat antiserum against rabbit IgG coupled to Texas- 
red at 37oC for 2∼3 hr and then washed 4 times 
in PBS. After 3 additional washes in PBS, the slides 
were mounted in mounting solution. Cells were view-
ed by confocal microscope (Lica PCSMT, Heidelberg, 
Germany) using the 100× objective lens.
Immunoprecipitation and Western blotting. 293T cells trans-
fected with CD8T or CD8-KIR were stimulated with 
OKT8 ascites (1：200 dilution). After 30 min stimu-
lation, the cells were rinsed twice with ice-cold PBS 
and lysed in a lysis buffer (10 mM Tris, pH 7.5, 1% 
Triton X-100, 150 mM NaCl, 10 mM Na3VO4, 1 mM 
NaF, 1 mM Na pyrophosphate, 5 mM EDTA, 50μg/ml 
leupeptin, 1 U/ml aprotinin, 1 mM pepstatin, 1 mM 
PMSF). Samples were incubated for 1hr at 4oC and 
centrifuged (13,000 rpm) for 20 min at 4oC. For 
immunoprecipitation, the lysates from 5×106 cells in 
700μl were precleared by mixing for 3 hr at 4oC with 
protein A agarose. The precleared lysates were then 
incubated with anti-Shc antibody on a rotating shaker 
for 1 hr at 4oC, and protein A agarose beads were 
added and further incubated overnight at 4oC. The 
precipitates were washed 4 times with wash buffer 
(cell lysis buffer with salt concentration increased by 
200% and detergent concentration decreased by 50%) 
and twice with 10 mM Tris (pH 7.5) containing 50 
mM NaCl and 0.1% triton X-100. After SDS PAGE, 
the proteins were transferred onto PVDF membrane, 
and blotted with anti-His-CytKIR antibodies. The 
membrane was reprobed with anti-SHP-2 antibody. A 
reciprocal immunoprecipitation experiment was also 
carried out with anti-His-CytKIR antibodies followed 
by immunoblotting with anti-Shc antibody and sub-
sequently with anti-SHP-2 antibody.
Results
The cytoplasmic tail of KIR associates with Shc, Grb2, TCR-
ζ and a protein of 36 kDa in Jurkat T cell lysates. Coag-
gregation of an activating receptor, such as TCR or 
FcR, and KIR is required for the inhibition of NK 
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or T cell activation (46,47), implying that the inhibit-
ory effect mediated by KIR may occur in the imme-
diate vicinity of the activating receptor. We first asked 
whether the cytoplasmic tail of KIR interacts with 
signaling molecules that are also associated with acti-
vating receptors, such as TCR, BCR and FcR. To 
identify proteins associated with the cytoplasmic tail 
of KIR, we generated a His-tag fusion protein of the 
cytoplasmic tail (His-CytKIR, Fig. 1A) and used this 
fusion protein to co-precipitate proteins from meta-
bolically-labeled Jurkat T cells. Ni-NTA resin was 
used to coprecipitate proteins interacting with the 
His-CytKIR. In Jurkat cell lysates, the cytoplasmic tail 
of KIR coprecipitated the proteins of 46 kDa, 36 
kDa, 23 kDa and 16 kDa (Fig. 2A, lane 2). The co-
precipitates appeared as higher Mr (50∼100 kDa) 
complexes under nonreducing conditions (Fig. 2A, la-
ne 3), suggesting that the four proteins are really cro-
ss-linked to His-CytKIR by DSP, a disulfide contain-
ing cross-linker. A control His-tag protein expressed 
from the pRSETA expression plasmid per se did not 
result in any detectable proteins coprecipitated in the 
cell lysates (Fig. 2A, lane 1). The protein bands were 
also detectable when the precipitates were obtained 
without a chemical cross-linking procedure (Fig. 2C 
for the 46 kDa protein; data for other proteins not 
shown), though less prominent than with chemical 
cross-linking. These results suggest that the cytoplas-
mic tail of KIR associates specifically with the 46 
kDa, 36 kDa, 23 kDa and 16 kDa proteins in Jurkat 
cell lysates.
  Previously, we identified that the 16 kDa protein 
is TCRζ by immunoblotting experiments with anti-
bodies against TCRα,β, CD3ε andζ (43). Intere-
stingly, we found that the remaining coprecipitated 
proteins of 46, 36 and 23 kDa have molecular weights 
consistent with Shc, pp36 (LAT) and Grb2, respec-
tively (36,48,49), that have been implicated to func-
tion in and downstream of TCR signal transduction. 
To identify the 46 kDa and 23 kDa proteins, we per-
formed immunoblotting experiments with commer-
cially available anti-Shc and anti-Grb2 antibodies. The 
results shown in Fig. 2B clearly indicate that the 46 
kDa and 23 kDa proteins are Shc and Grb2, re-
spectively. Mammalian Shc exists in three isoforms of 
46 kDa, 52 kDa and 66 kDa, but only the former 
two are expressed by hematopoietic cells (36). Our 
Figure 1. His-tag and CD8 fusion protein constructs. (A) The
His-CytKIR construct encodes a His-tag fusion protein of the
cytoplasmic tail of a p70 KIR (NKB1). The protein coding region
of the cytoplasmic tail of KIR was subcloned into an E. coli ex-
pression vector pRSETA. The His-tag construct (pRSETA itself)
encodes a control His-tag fusion protein which lacks the cyto-
plasmic tail of KIR. (B) The CD8 fusion protein constructs. The
generation of plasmid containing the extracellular and transmem-
brane portion of CD8α, pCD8T, was described previously (44).
A CD8 fusion construct of KIR was generated by subcloning



















Figure 2. The His-CytKIR associates with Shc, Grb2, TCRζ,
and a protein of 35 kDa in Jurkat T cell lysates. (A) His-CytKIR
was mixed with [35S] labeled Jurkat cell lysates and cross-linked
with DSP. The His-CytKIR was precipitated with Ni-NTA resin,
and the precipitates were resolved by SDS-PAGE under reducing
(lane 2) and nonreducing (lane 3) conditions. (B) The 46 kDa
and 23 kDa proteins are Shc and Grb2, respectively. The His-
CytKIR and Jurkat cell lysates were mixed and incubated for 1
hr at 4oC. The His-CytKIR was precipitated with Ni-NTA resin,
and the precipitates were resolved on SDS gels. The protein
bands were detected with anti-Shc (upper pannel) and anti-Grb2
(lower pannel) antibodies. (C) Similar experiments with (B) were
performed with (lane 2) and without (lane 3) chemical cross-
linking. The precipitates were detected with anti-Shc antibody.
Lane 1 in each figure shows the precipitates obtained by using 
the His-tag control protein in the reaction mixtures.
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results show that only the 46 kDa form of Shc asso-
ciates with His-CytKIR in Jurkat cell lysates. 
Phosphorylated KIR cytoplasmic tail binds SHP-1 and Shc 
in Jurkat T cell lysates. To investigate the effect of tyro-
sine phosphorylation on the molecular association be-
tween KIR and the signaling molecules, we carried 
out similar His-tag pull-down experiments. Metaboli-
cally-labeled Jurkat cell lysates were mixed with His- 
CytKIR in a kinase reaction buffer and incubated at 
37oC as previously described (42,43). The reaction 
mixtures were chemically cross-linked and precipi-
tated with Ni-NTA resin. The precipitates were sepa-
rated on a SDS polyacrylamide gel and the protein 
bands were visualized by autoradiography. Unlike the 
unphosphorylated His-CytKIR (Fig. 2A), the phos-
phorylated His-CytKIR was associated with the 68 
kDa and 46 kDa proteins (Fig. 3A), which turned out 
to be SHP-1 and Shc, respectively, by Western blot 
experiments (data not shown). These results are con-
sistent with previous reports showing that the pho-
Figure 3. Tyrosine phosphorylated His-CytKIR associates with
SHP-1 and Shc in Jurkat T cell lysates. (A) His-CytKIR was
mixed with [35S] labeled Jurkat cell lysates in a Kinase reaction
buffer and incubated at 37oC. The reaction mixtures were cross-
linked with DSP, and the His-CytKIR was precipitated with Ni-
NTA resin. The precipitates were resolved by SDS-PAGE under
reducing (lane 2) and nonreducing (lane 3) conditions. Lane 1
shows the precipitates obtained by using the His-tag control
protein in the reaction mixtures. (B) Effects of tyrosine phospho-
rylation of KIR on the Shc and Grb2 binding. Same amounts
of Jurkat cell lysates (500 μg) and the His-CytKIR protein (200
μg) were mixed in a kinase reaction buffer (total volume of 700
μl) and cross-linked with DSP. In vitro phosphorylation reactions
were performed in the presence (lane 4) and absence (lane 3)
of sodium orthovanadate, a protein tyrosine phosphatase inhibi-
tor (58). Then the His-CytKIR was precipitated with Ni-NTA
resin and the precipitates were detected with anti-Shc antibody
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Figure 4. Expression of CD8-KIR on 293T cells and the colo-
calization of CD8-KIR and Shc in transfected cells. 293T cells
were transiently transfected with the CD8T and CD8-KIR con-
structs, respectively. (A) A histogram shows the surface expre-
ssion level of transfected CD8-KIR as determined by FACS sta-
ining with PE-conjugated anti-CD8 antibody, where shaded his-
togram indicates staining with PE-conjugated anti-mouse IgG. (B)
Expression level of transfected CD8-KIR protein was detected
by immunoblotting with polyclonal anti-His-CytKIR antibodies.
Extracts from 5×103 cells were loaded. Lane 1 is 293T cells
transfected with CD8T; lane 2 is 293T cells transfected with
CD8-KIR; lane 3 is 293T cells transfected with CD8-KIR and
stimulated with PMA/Ionomycin. (C-F) Colocalization of Shc
and CD8-KIR by confocal microscopy in transfected 293T cells. 
Cells were double-labeled with anti-Shc antibody (red, detected
with Texas red-conjugated goat anti-rabbit IgG) and with mouse
antiserum to CD8 (green, detected with FITC-conjugated goat
anti-mouse Ig). Fluorescent confocal images were obtained for
Shc expression (red) in transfected (C) and untransfected (E) 
cells, and CD8-KIR expression (green, D). The two images were
then superimposed (F) to show regions expressing both Shc and
CD8-KIR (yellow). 
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sphorylated KIR recruits SHP-1 (21-24,31), and that 
the synthetic peptide representing the phosphorylated 
form of the ITIM of FcγRIIB binds Shc (50). Previ-
ous studies have also shown that Shc associates with 
tyrosine phosphorylated TCRζ and Grb2 (51) in T 
cells, both of which also appeared to associate with 
KIR in this report. However, in contrast to TCRζ 
(43) and Grb2 (Fig. 3B, middle), Shc appeared to 
associate with both phosphorylated (Fig. 3B, top, lane 
3) and non-phosphorylated His-CytKIR (lane 2). As 
well, Shc binding was most prominent among the 
proteins associating with His-CytKIR (Fig. 2A). 
These findings suggest that Shc directly associates 
with His-CytKIR, not through the TCRζ or Grb2.
Interaction of KIR and Shc in transfected cells. To verify 
the association of KIR and Shc in cells, a CD8 fusion 
protein construct of KIR cytoplasmic tail (CD8-KIR, 
Fig. 1B) was transfected into 293T cells. FACS stain-
ing with a monoclonal antibody to CD8 (OKT8) and 
Western blot analysis with polyclonal antibodies to 
the His-CytKIR protein showed that CD8-KIR was 
expressed on the surface of 293T cells (Fig. 4A, B, 
respectively). We next investigated whether the CD8- 
KIR expressed on 293T cells interacts with Shc. The 
transfected cells were double stained with anti-Shc 
antibody and OKT8, and then observed on a con-
focal microscope. Most of the transfected cells abun-
dantly expressed CD8-KIR, and the CD8-KIR ap-
peared to be localized predominantly on the cell sur-
face (Fig. 4D). In 293T cells, Shc protein was found 
in the cytoplasm as well as around the plasma mem-
brane (Fig. 4E). However, in 293T cells transfected 
with the CD8-KIR expression vector, most of Shc 
appeared to be localized around the plasma mem-
brane (Fig. 4C). Double staining of the transfected 
cells clearly showed that CD8-KIR and Shc were co-
localized on the membrane (Fig. 4F), suggesting that 
the two proteins associate in the mammalian cells.
  The binding interaction between the CD8-KIR and 
Shc in transfected cells was confirmed by coimmuno-
precipitation analysis. Shc was immunoprecipitated 
with anti-Shc antibody, and the precipitates were re-
solved on a SDS polyacrylamide gel. The protein bands 
were transferred onto PVDF membrane, and sequen-
tially blotted with anti-His-CytKIR antibody and anti- 
SHP-2 antibody, respectively. Fig. 5A shows that 
CD8-KIR coprecipitated with Shc (Fig. 5A, top, lane 
3). Interestingly, however, the association was almost 
blocked when the CD8-KIR was cross-linked by 
OKT8 antibody prior to the anti-Shc immunoprecipi-
tation (lane 4). On the other hand, SHP-2 binding 
was only observed when the transfectants were treat-
ed with OKT8 antibody cross-linking (Fig. 5A, bot-
tom, lane 4). The weak intensity of the SHP-2 band 
may result from the fact that most of the phosphory-
lated KIR could not precipitate with Shc. Immuno-
precipitation with anti-His-CytKIR antibodies and im-
munoblotting experiments with anti-Shc and anti- 
SHP-2 antibodies resulted in similar results (Fig. 5B). 
Shc coprecipitated with CD8-KIR and the association 
was greatly reduced by OKT8 antibody cross-linking 
(Fig. 5B, top). Both the 46 kDa and 52 kDa forms 
of Shc appeared to associate with the CD8-KIR in 
transfected cells. However, SHP-2 binding was not 
detected in this case (Fig. 5B, bottom), probably due 
to the antibody blocking effect. Taken together, these 
results indicate that CD8-KIR constitutively interacts 
with Shc in 293T cells but the Shc is replaced by 
SHP-2 upon engagement of CD8-KIR.
Discussion
  By in vitro coprecipitation experiments, we demon-
strated that the cytoplasmic tail of KIR associates 
with proteins of 46 kDa, 36 kDa, 23 kDa, and 16 
kDa in Jurkat T cell lysates. Previously, we identified 
that the 16 kDa protein is TCRζ and demonstrated 
that the association between KIR and TCRζ is 
hindered by the tyrosine phosphorylation of KIR, but 
is independent of the tyrosine phosphorylation of the 
TCRζ-chain (43). In this report, we identified that 
the 46 kDa and 23 kDa proteins are Shc and Grb2, 
respectively, by immunoblotting experiments. Like 
the case of TCRζ, tyrosine phosphorylation of the 
KIR cytoplasmic tail abolished the association with 
Grb2 and the 36 kDa protein in Jurkat cell lysates. 
However, the interaction between KIR and Shc ap-
Figure 5. Association of CD8-KIR and Shc in 293T cells 
transiently transfected with CD8-KIR. CD8-KIR associates Shc
in resting 293T cells, but it associates SHP-2 instead of Shc in
cells treated with anti-CD8 antibody. (A) Shc was immunopreci-
pitated with anti-Shc antibody and blotted with anti-His-CytKIR
antibody (top), and reprobed with anti-SHP-2 antibody (bottom).
(B) Shc was immunoprecipitated with anti-Shc antibody and
blotted with anti-His-CytKIR antibody (top), and reprobed with
anti-SHP-2 antibody (bottom). Lanes in (A, B): lane 1, 293T cells
transfected with CD8T; lane 2, 293T cells transfected with CD8T
and treated with anti-CD8 antibody; lane 3, 293T cells transfected
with CD8-KIR; lane 4, 293T cells transfected with CD8-KIR and
treated with anti-CD8 antibody.
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peared to be unaffected in vitro. The relatively weak 
band intensity of Grb2 (Fig. 2A) and previous re-
ports, where Grb2 appears to associate with Shc, 
TCRζ, and LAT (51), suggest that Grb2 may be co-
precipitated with other proteins. We also demonstra-
ted that tyrosine phosphorylated KIR associates with 
SHP-1 and Shc in Jurkat T cell lysates, suggesting 
that the molecular interaction between KIR and the 
signaling molecules identified in this study are diffe-
rently modulated by the phosphorylation status of 
KIR. 
  To investigate the molecular interaction between 
KIR and Shc in cells, we transfected the CD8-KIR 
expression vector in 293T cells. Double staining of 
the transfectants with anti-Shc antibody and OKT8 
antibody revealed that CD8-KIR and Shc are colo-
calized around the plasma membrane, and immuno-
precipitation analysis confirmed that CD8-KIR binds 
Shc in transfected cells. In contrast to the in vitro 
data, however, KIR interacts with Shc in a phos-
phorylation-dependent manner in cells. Shc binds to 
CD8-KIR in resting cells, but dissociates in OKT8 
treated-cells. Upon engagement of CD8-KIR with 
OKT8 antibody, KIR appears to associate with SHP- 
2 instead of Shc, suggesting that the phosphorylation 
of tyrosine residues in the KIR cytoplasmic tail hin-
ders Shc binding and induces SHP-2 (maybe SHP-1 
in NK and T cells) binding in 293T cells where no 
SHP-1 is expressed (our unpublished observation). 
The in vitro association of Shc with the phosphory-
lated KIR may be caused by either incomplete phos-
phorylation of KIR or excess use of KIR for the in 
vitro coprecipitation experiments. Also, the associa-
tion between KIR and Grb2 observed in in vitro 
experiments was not detected in transfection analysis. 
This result suggests that Grb2 may be coprecipitated 
with TCRζ or the 36 kDa protein which are not ex-
pressed in 293T cells but are present in Jurkat T cells.
  Shc is composed of three different domains, a 
phospho-tyrosine binding domain (PTB), collagen ho-
molog domain (CH), and SH2 domain (36-38). Our 
data demonstrate that unphosphorylated KIR binds 
to Shc, but the KIR：Shc complex dissociates upon 
tyrosine phosphorylation of KIR, suggesting that Shc 
may bind around the ITIMs of KIR. This is quite 
distinct from the common binding modes of the SH2 
and PTB domains, which bind only with phospho-
rylated tyrosine sites. As well, the CH domain is 
known to bind with Grb2 via phosphorylated tyro-
sine residue. Therefore, the binding mode between 
KIR and Shc seems to be unique. Interestingly, we 
have shown that the His-CytKIR binds only the 46 
kDa form of Shc in Jurkat cell lysates, while the 
CD8-KIR and endogenous KIR bind the 46 kDa and 
52 kDa forms of Shc in 293T cells and in NK and 
T cells, respectively. The 46 kDa form is distinct 
from the 52 kDa form only at the N-terminus, where 
about 50 amino acid residues are truncated in the 46 
kDa form by an alternative translation mechanism 
(36). Also, the 66 kDa form of Shc has an additional 
CH domain at the N-terminus of the 52 kDa form 
(39). Taken together, the KIR binding sites on the 
Shc molecule seems to be located at the N-terminal 
region.
  We demonstrated that the cytoplasmic tail of KIR 
constitutively associates with Shc in vitro as well as in 
cells. It would be interesting to investigate the func-
tional implications of this observation. Shc proteins 
recruited by a variety of activated receptors mediate 
the activation of the Ras signaling pathway through 
the complex formation of Grb2：SOS (39,51,52). We 
investigated whether Shc bound to KIR would also 
turn on the Ras signaling pathway. However, no 
direct evidence suggesting that the Ras signaling path-
way is activated by overexpressing CD8-KIR in 293T 
cells was obtained (data not shown). CD8-KIR：Shc 
association was evident, but Shc：Grb2 association 
was not observed in the transfected cells. Further-
more, no MAP kinase activation was observed in the 
transfectants even after the engagement of CD8-KIR 
with OKT8 antibody. Recent studies have implied 
that Shc might send another signal distinct from Ras 
activation for an anti-apototic pathway (53), for 
mitogenesis of fibroblast and Drosophila cells (54,55), 
and for cellular transformation (56). Interestingly, it 
has been demonstrated that human cytotoxic T cells 
that express KIR represent oligoclonally or mono-
clonally-expanded cell populations (57). In addition, 
KIR expressed on T cells has been shown to inhibit 
the activation-induced cell death of T cells in a 
ligation-independent manner by blocking FasL induc-
tion upon stimulation (9,12). Furthermore, KIR ex-
pressing clones demonstrated greater forward scatter 
values by FACS analysis and larger cell sizes by image 
analysis (12). These observations suggest that KIR 
might constitutively transmit a certain signal that 
affects the cell size and the growth pattern of Jurkat 
T cells.
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